dexborneol/cilostazol (Y-6 sublingual) / NeuroDawn - LARVOL DELTA

Sublingual Cilostazol and Dexborneol for the Treatment of Acute Ischemic Stroke:A Randomized Clinical Trial (ISC 2026) - P2 | "The symptomatic intracranial hemorrhage at 28 days occurred in 1 patient (1.8%) in Y-6 high-dose group, 3 patients (4.8%) in Y-6 low-dose group, 2 patients (3.3%) in cilostazol high-dose group, 4 patients (6.8%) cilostazol low-dose group and 2 patients (3.6%) in placebo group.Conclusions The findings suggested that for ischemic stroke patients undergoing endovascular treatment, the Y-6 sublingual tablets showed the trend of improving functional outcomes as it did not reach statistical significance; while it did not associate with the symptomatic intracranial hemorrhage events. Further research should be conducted to prove in large-scale phase 3 clinical trials."

Clinical • Late-breaking abstract • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Phase III Clinical Trial of Y-6 Sublingual Tablets for the Treatment of Acute Ischemic Stroke - A Multicenter, Randomized, Double-Blind, Placebo-Parallel Controlled Trial (ChiCTR) - P3 | N=892 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital Affiliated to Capital Medical University; NeuroDawn Pharmaceutical Co., Ltd.

New P3 trial • Cardiovascular • Ischemic stroke

Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke (clinicaltrials.gov) - P3 | N=892 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital

New P3 trial • Cardiovascular • Ischemic stroke